1,218.44
price down icon1.44%   -17.12
 
loading
Lilly Eli Co stock is traded at $1,218.44, with a volume of 1.76M. It is down -1.44% in the last 24 hours and up +5.97% over the past month. Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,235.56
Open:
$1221.095
24h Volume:
1.76M
Relative Volume:
0.55
Market Cap:
$1.09T
Revenue:
$72.25B
Net Income/Loss:
$25.28B
P/E Ratio:
43.86
EPS:
27.781
Net Cash Flow:
$10.37B
1W Performance:
+2.18%
1M Performance:
+5.97%
6M Performance:
+12.21%
1Y Performance:
+56.59%
1-Day Range:
Value
$1,204.16
$1,241.89
1-Week Range:
Value
$1,180.30
$1,249.45
52-Week Range:
Value
$623.78
$1,249.45

Lilly Eli Co Stock (LLY) Company Profile

Name
Name
Lilly Eli Co
Name
Phone
(317) 276-2000
Name
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Name
Employee
50,000
Name
Twitter
@LillyPad
Name
Next Earnings Date
2026-08-05
Name
Latest SEC Filings
Name
LLY's Discussions on Twitter

Compare LLY vs JNJ, ABBV, MRK, NVS

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
LLY icon
LLY
Lilly Eli Co
1,220.00 1.10T 72.25B 25.28B 10.37B 27.78
JNJ icon
JNJ
Johnson Johnson
265.14 643.30B 96.36B 21.04B 17.80B 8.6488
ABBV icon
ABBV
Abbvie Inc
252.88 449.91B 62.82B 3.60B 19.98B 2.0274
MRK icon
MRK
Merck Co Inc
126.50 318.26B 65.51B 8.93B 14.12B 3.5532
NVS icon
NVS
Novartis Ag Adr
155.44 299.63B 54.66B 13.58B 16.05B 7.0171

Lilly Eli Co Stock (LLY) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-17-26 Downgrade HSBC Securities Hold → Reduce
Feb-25-26 Initiated RBC Capital Mkts Outperform
Feb-20-26 Initiated Barclays Overweight
Jan-07-26 Resumed UBS Buy
Dec-16-25 Upgrade Daiwa Securities Neutral → Buy
Dec-15-25 Reiterated BofA Securities Buy
Dec-15-25 Reiterated Goldman Buy
Nov-13-25 Initiated Scotiabank Sector Outperform
Nov-10-25 Upgrade Leerink Partners Market Perform → Outperform
Oct-20-25 Reiterated BMO Capital Markets Outperform
Oct-14-25 Upgrade Erste Group Hold → Buy
Sep-17-25 Downgrade Berenberg Buy → Hold
Aug-27-25 Upgrade HSBC Securities Reduce → Hold
Aug-18-25 Downgrade Daiwa Securities Outperform → Neutral
Aug-07-25 Downgrade Leerink Partners Outperform → Market Perform
Jun-05-25 Downgrade Erste Group Buy → Hold
Apr-28-25 Downgrade HSBC Securities Buy → Reduce
Apr-22-25 Initiated Cantor Fitzgerald Overweight
Dec-10-24 Resumed BofA Securities Buy
Nov-15-24 Initiated Wolfe Research Outperform
Oct-17-24 Initiated Bernstein Outperform
Sep-13-24 Resumed Citigroup Buy
Aug-12-24 Upgrade Deutsche Bank Hold → Buy
Feb-21-24 Downgrade DZ Bank Buy → Hold
Feb-16-24 Reiterated Morgan Stanley Overweight
Dec-21-23 Downgrade Daiwa Securities Buy → Outperform
Nov-09-23 Initiated Deutsche Bank Hold
Oct-20-23 Resumed UBS Buy
Aug-09-23 Upgrade Jefferies Hold → Buy
Jul-26-23 Reiterated Citigroup Buy
Jul-14-23 Initiated HSBC Securities Buy
May-24-23 Reiterated BofA Securities Buy
May-24-23 Reiterated UBS Buy
Mar-13-23 Upgrade Wells Fargo Equal Weight → Overweight
Mar-06-23 Initiated Jefferies Hold
Feb-15-23 Downgrade Societe Generale Hold → Sell
Nov-18-22 Initiated Credit Suisse Outperform
Sep-22-22 Upgrade UBS Neutral → Buy
May-23-22 Initiated SVB Leerink Outperform
Apr-06-22 Resumed Morgan Stanley Overweight
Mar-10-22 Initiated Daiwa Securities Outperform
Jan-21-22 Upgrade DZ Bank Hold → Buy
Jan-03-22 Reiterated Bernstein Mkt Perform
Dec-17-21 Initiated Goldman Neutral
Dec-16-21 Reiterated BMO Capital Markets Outperform
Dec-16-21 Reiterated BofA Securities Buy
Dec-09-21 Resumed Wells Fargo Equal Weight
Nov-19-21 Initiated BMO Capital Markets Outperform
Oct-11-21 Upgrade Berenberg Hold → Buy
Sep-29-21 Upgrade Citigroup Neutral → Buy
Aug-05-21 Upgrade DZ Bank Hold → Buy
Jul-27-21 Resumed Truist Buy
Jun-24-21 Reiterated Cantor Fitzgerald Overweight
Jan-19-21 Upgrade Mizuho Neutral → Buy
Dec-10-20 Upgrade Wolfe Research Peer Perform → Outperform
Nov-10-20 Resumed Bernstein Mkt Perform
Sep-29-20 Initiated Berenberg Hold
Sep-03-20 Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-16-20 Upgrade Guggenheim Neutral → Buy
Apr-21-20 Downgrade UBS Buy → Neutral
Apr-09-20 Downgrade Morgan Stanley Overweight → Equal-Weight
Feb-06-20 Initiated Mizuho Neutral
Dec-18-19 Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-17-19 Resumed BofA/Merrill Buy
May-28-19 Initiated Goldman Buy
Apr-24-19 Upgrade Edward Jones Hold → Buy
Apr-11-19 Downgrade Guggenheim Buy → Neutral
Mar-12-19 Initiated JP Morgan Overweight
Jan-23-19 Initiated UBS Buy
Nov-26-18 Downgrade Citigroup Buy → Neutral
Oct-31-18 Upgrade Credit Suisse Underperform → Neutral
Oct-09-18 Initiated Guggenheim Buy
Oct-01-18 Reiterated SunTrust Buy
Sep-26-18 Resumed JP Morgan Overweight
View All

Lilly Eli Co Stock (LLY) Latest News

pulisher
12:02 PM

Wall Street Is Betting on Eli Lilly’s GLP-1 Portfolio — It’s Missing the $1 Trillion Opportunity - 24/7 Wall St.

12:02 PM
pulisher
11:56 AM

Eli Lilly (NYSE:LLY) Faces A Valuation Test - Kalkine Media

11:56 AM
pulisher
11:27 AM

RBC stated that Eli Lilly and Co's obesity and diabetes drug businesses will drive second-quarter sales above expectations. - 富途牛牛

11:27 AM
pulisher
09:59 AM

Truist raises Eli Lilly stock price target on incretin strength - Investing.com

09:59 AM
pulisher
09:43 AM

Truist raises Eli Lilly stock price target on incretin strength By Investing.com - Investing.com Canada

09:43 AM
pulisher
09:21 AM

A Quick Look at Today's Ratings for Eli Lilly and Co(LLY.US), With a Forecast Between $1,347 to $1,500 - Moomoo

09:21 AM
pulisher
09:02 AM

Truist Securities Raises Price Target on Eli Lilly to $1,370 From $1,281, Keeps Buy Rating - Moomoo

09:02 AM
pulisher
09:00 AM

Lilly Canada receives long-awaited Ebglyss® CDA-AMC recommendation as well as pCPA LOI for atopic dermatitis (eczema) - Newswire Canada

09:00 AM
pulisher
08:30 AM

Prediction: Eli Lilly Stock Will Hit This Price by the End of 2026 - The Motley Fool

08:30 AM
pulisher
08:05 AM

Eli Lilly (LLY) Stock Still Looks Below Fair Value Despite Rich Earnings - simplywall.st

08:05 AM
pulisher
04:53 AM

Eli Lilly & Co. focuses on long-term growth as investors track its pipeline - AD HOC NEWS

04:53 AM
pulisher
Jul 07, 2026

Why Eli Lilly Stock Climbed to a Record High Today - AOL.com

Jul 07, 2026
pulisher
Jul 07, 2026

Fla. Hospital Says Lilly's 340B Data Requirement Is Onerous - Law360

Jul 07, 2026
pulisher
Jul 07, 2026

Migraine Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | GlaxoSmithKline, Merck, Pfizer, Bausch Health, Amgen, Abbvie, AstraZeneca, Eli Lilly - Barchart.com

Jul 07, 2026
pulisher
Jul 07, 2026

Why Eli Lilly (LLY) Stock Is Trading Up Today - Yahoo Finance

Jul 07, 2026
pulisher
Jul 07, 2026

Form 144 ELI LILLY AND COMPANY For: 7 July By Investing.com - Investing.com Canada

Jul 07, 2026
pulisher
Jul 07, 2026

Lilly Endowment (LLY) reports multiple stock sales, May–June 2026 - Stock Titan

Jul 07, 2026
pulisher
Jul 07, 2026

Tampa General sues Eli Lilly over alleged 'illegal' cutoff of discounted drug pricing - The Business Journals

Jul 07, 2026
pulisher
Jul 07, 2026

Is Eli Lilly (NYSE:LLY) Still A Blue-Chip Leader? - Kalkine Media

Jul 07, 2026
pulisher
Jul 07, 2026

Mounjaro from Eli Lilly and Co.weekly injection reshapes US weight-loss market - AD HOC NEWS

Jul 07, 2026
pulisher
Jul 07, 2026

Eli Lilly Seen Raising Guidance on Continued GLP-1 Growth -- Market Talk - Moomoo

Jul 07, 2026
pulisher
Jul 07, 2026

Eli Lilly Stock Hits a New All-Time High: Has It Gotten Too Expensive to Buy? - The Motley Fool

Jul 07, 2026
pulisher
Jul 07, 2026

Factbox-Weight-loss drug developers line up to tap lucrative market as competition heats up - Yahoo! Finance Canada

Jul 07, 2026
pulisher
Jul 07, 2026

Eli Lilly and Co Stock (LLY) Moved Up by 3.08% on Jul 7: Facts Behind the Movement - TradingKey

Jul 07, 2026
pulisher
Jul 07, 2026

Eli Lilly Gains as Investors Lean Into Obesity Franchise Momentum - Quiver Quantitative

Jul 07, 2026
pulisher
Jul 07, 2026

Eli Lilly (LLY) Expands Mounjaro Use for Pediatric Diabetes Mana - GuruFocus

Jul 07, 2026
pulisher
Jul 07, 2026

Eli Lilly (NYSE:LLY) Faces A Big GLP Test - Kalkine Media

Jul 07, 2026
pulisher
Jul 07, 2026

LLY: JPMorgan Raises Eli Lilly Price Target Amid Strong Earnings Outlook - GuruFocus

Jul 07, 2026
pulisher
Jul 07, 2026

Eli Lilly stock hits all-time high at 1238.06 USD By Investing.com - Investing.com Canada

Jul 07, 2026
pulisher
Jul 07, 2026

LLY Maintained by JP Morgan -- Price Target Raised to $1400 - GuruFocus

Jul 07, 2026
pulisher
Jul 07, 2026

A Quick Look at Today's Ratings for Eli Lilly and Co(LLY.US), With a Forecast Between $1,350 to $1,400 - 富途牛牛

Jul 07, 2026
pulisher
Jul 07, 2026

Can anyone catch up to Eli Lilly? - Pharma Voice

Jul 07, 2026
pulisher
Jul 07, 2026

Is It Too Late to Buy Eli Lilly Stock? Here's What $1,000 Invested Today Could Be Worth in 10 Years. - Yahoo Finance

Jul 07, 2026
pulisher
Jul 07, 2026

JPMorgan Adjusts Price Target on Eli Lilly to $1,400 From $1,300 - Moomoo

Jul 07, 2026
pulisher
Jul 07, 2026

Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,400 - 富途牛牛

Jul 07, 2026
pulisher
Jul 07, 2026

Eli Lilly stock holds the spotlight. Company identity is confirmed. - AD HOC NEWS

Jul 07, 2026
pulisher
Jul 07, 2026

Eli Lilly (LLY) Could Be 19% Undervalued Following Medicare GLP 1 Expansion - simplywall.st

Jul 07, 2026
pulisher
Jul 06, 2026

Eli Lilly (LLY) Expands R And D Reach With Abbisko And China Drug Handover - Yahoo Finance

Jul 06, 2026
pulisher
Jul 06, 2026

LLY News | ELI LILLY & CO (NYSE:LLY) - ChartMill

Jul 06, 2026
pulisher
Jul 06, 2026

What Eli Lilly Stock Said When It Had Too Much Business - Yahoo Finance

Jul 06, 2026
pulisher
Jul 06, 2026

Eli Lilly (NYSE:LLY): Can GLP-1 Access Widen? - Kalkine Media

Jul 06, 2026
pulisher
Jul 06, 2026

Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026? - The Motley Fool

Jul 06, 2026
pulisher
Jul 06, 2026

Eli Lilly and Company (LLY) Fell on Regulatory And Pricing Policy Challenges - Yahoo Finance

Jul 06, 2026
pulisher
Jul 06, 2026

Cantor Fitzgerald raises Eli Lilly stock price target on strong outlook - Investing.com

Jul 06, 2026
pulisher
Jul 06, 2026

Could Buying Eli Lilly Stock Today Set You Up for Life? (Hint: Yes.) - Yahoo Finance

Jul 06, 2026
pulisher
Jul 06, 2026

Eli Lilly and Company (LLY) Stock Analysis: Investor Outlook on a $1.08 Trillion Healthcare Giant - DirectorsTalk Interviews

Jul 06, 2026
pulisher
Jul 05, 2026

Is Illumina (ILMN) Quietly Recasting Its Clinical Genomics Strategy With Eli Lilly’s R&D Chief on Board? - simplywall.st

Jul 05, 2026
pulisher
Jul 05, 2026

LLYLilly(Eli) & Co Latest SEC Filings - Finviz

Jul 05, 2026
pulisher
Jul 05, 2026

Eli Lilly Stock (LLY) Opinions on Medicare Coverage and Drug Pipeline Advancements - Quiver Quantitative

Jul 05, 2026
pulisher
Jul 05, 2026

Eli Lilly and Co. | Pharmaceuticals, Biomedical Research, & Company - Encyclopedia Britannica

Jul 05, 2026
pulisher
Jul 05, 2026

Should Expanded Medicare GLP‑1 Access and New Oncology Wins Require Action From Eli Lilly (LLY) Investors? - simplywall.st

Jul 05, 2026

Lilly Eli Co Stock (LLY) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
JNJ JNJ
$265.17
price down icon 0.81%
$252.77
price down icon 0.69%
MRK MRK
$126.56
price down icon 1.82%
NVS NVS
$155.33
price down icon 0.98%
AZN AZN
$189.59
price down icon 1.78%
Cap:     |  Volume (24h):